MTWC for Fibrosing Lung Disease Lecture Series – mTOR, Lung Proteolysis and Repair in Lymphangioleiomyomatosis | Events


We are delighted to be able to inform you about the May MTWC Lecture Series Seminar on Fibrotic Lung Diseases, which will be held on Thusday 12and May. At this session we will welcome our speaker at the Imperial Professor Simon Johnson, University of Nottingham.

Talk about the details as follows:-

Talk title: mTOR, Lung proteolysis and repair in lymphangioleiomyomatosis

Date: Thursday 12and May

Talk time: 4:00 p.m. – 5:00 p.m. UK time

Location: Paul Wood Reading Theatre, Guy Scadding Building, Brompton Campus, Cale Street, London, SW3 6LY East or online via Microsoft Teams (you will receive a link to the conference once you register)

Please complete the form in this link to confirm your place – either in person or online.

More information – Simon Johnson:

Clinical interests

respiratory medicine; Interstitial lung disease; Lymphangioleiomyomatosis; Rare lung disease.

Airway remodeling in asthma is categorized by airway smooth muscle hypertrophy and hyperplasia, alteration in the type and amount of extracellular matrix, epithelial shedding, and hyperplasia of mucous glands. Our interest is in how airway proteases and myofibroblast/extracellular matrix interactions affect myofibroblast growth and behavior. These studies utilize primary airway cell culture, co-cultures, protein expression, real-time PCR, and proteomics.

Lymphangioleiomyomatosis (LAM) is a rare lung and lymphatic disease classified by infiltration of smooth muscle-like cells into the lungs and lymphatics leading to progressive respiratory failure. The disease only affects women and is caused by a defect in one of the two proteins associated with tuberous sclerosis, tuberine and hamartin. Our group has a clinical interest in AML, manages the UK AML database and is involved in a number of studies and clinical trials.

Laboratory research projects in LAM include mechanisms of lung destruction in LAM, prognostic biomarkers, and generation of model systems to study LAM.

Matrix metalloproteinases are proteolytic enzymes secreted by a range of cells and regulated by pro-inflammatory cytokines, growth factors and extracellular matrix. We have studied them in airway myofibroblasts as well as in specific diseases including chronic obstructive pulmonary disease and LAM.

Questions will be asked of those attending in person, but if you would like to submit a question ahead of the event, please send it to

Supported by


Comments are closed.